- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT03978780
Bloqueio do Eretor da Espinha vs. Estudo de Bloqueio com Placebo
Pontuações de qualidade de recuperação após bloqueio do eretor da espinha vs. bloqueio simulado em cirurgia ambulatorial de câncer de mama: um estudo controlado randomizado
Regional anaesthesia combined with general anaesthesia has become common in the perioperative management of breast cancer surgery patients. Regional techniques have been recognised to provide excellent post-operative analgesia. It enhances multi-modal analgesia regimes while being opioid sparing, reducing incidence of post-operative nausea and vomiting and allowing earlier mobilisation/discharge and improving treatment success. Therefore identifying the correct regional anaesthetic technique for this group of patients is important in providing optimum peri-operative care.
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
The ultrasound-guided erector spinae plane (ESP) block has been recently described for the successful management of thoracic neuropathic pain. The erector spinae muscle is formed by the spinalis, longissimus thoracis, and iliocostalis muscles that run vertically in the back. The ESP block is performed by depositing the local anaesthetic in the fascial plane, deep to the erector spinae muscle, at the tip of the transverse process of the vertebra. Indirect access to the paravertebral space is gained providing analgesia without the risk of needle injury to structures in close proximity. Cadaveric studies have shown both ventral and dorsal rami of thoracic spinal nerves are affected when local anaesthetic is injected deep to the erector spinae muscle. The erector spinae muscle extends along the thoracolumbar spine allowing extensive cranio-caudal spread. The ventral ramus (intercostal nerve) is divided into the anterior and lateral branches. Its terminal branches provide the sensory innervation of the entire anterolateral wall. The dorsal ramus is divided into 2 terminal branches and it gives the sensory innervation to the posterior wall. Anterior spread of the local anaesthetic to the paravertebral space through the costotransverse foramina and the intertransverse complex provides both visceral and somatic analgesia.
While recent evidence supports statistically significant reductions in pain and opioid consumption among patients who receive an ESP block compared to systemic analgesia alone, the clinical significance of these differences are questionable the effect of ESP block on the patients' quality of recovery following ambulatory breast cancer surgery remains unclear.
Therefore, our objective is to determine whether or not the addition of an ESP block provides both superior analgesia and quality of recovery in patients undergoing ambulatory breast cancer surgery compared to systemic analgesia alone. We hypothesis that patients who received a preoperative ESP block will afford superior postoperative analgesia and improve the quality of recovery over the first 24 hours following surgery compared to those who receive a sham block for their ambulatory breast cancer surgery.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Ontario
-
Toronto, Ontario, Canadá, M5S 1B2
- Women's College Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- ASA classification: I-III
- BMI < 35 kg/m2
- Day surgery procedure
Exclusion Criteria:
- Prior ipsilateral breast surgery, excluding lumpectomy
- Pre-existing neurological deficit or peripheral neuropathy involving the ipsilateral chest
- Severe, poorly controlled cardiac conditions, significant arrhythmias, severe valvular heart diseases
- Severe, poorly controlled respiratory conditions (severe COPD, severe interstitial lung disease, severe / poorly controlled asthma)
- Contraindication to regional anaesthesia (e.g. bleeding diathesis, coagulopathy, sepsis, infection at the site of potential needle puncture on the posterior chest)
- Patient refusal
- Chronic pain disorder
- Chronic opioid use (≥30 mg oxycodone / day)
- Contraindication (or allergy) to a component of multi-modal analgesia protocol
- Allergy to amide local anaesthetics used in nerve blocks
- Contraindications to any of the components of the standardized general anaesthesia
- Significant psychiatric disorder that would preclude objective study assessment
- Pregnancy/ women with nursing infants
- Unable to provide informed consent
- Unable to speak and read English
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Triplo
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador de Placebo: Control Group
Patients randomised to the Control group will then receive a sham subcutaneous injection of 0.5ml normal saline injected at the same site as the ESP block (see above) under ultrasound guidance to stimulate a real block procedure. |
Patients randomised to the Control group will then receive a sham subcutaneous injection of 0.5ml normal saline injected at the same site as the ESP block under ultrasound guidance to stimulate a real block procedure. |
|
Experimental: Erector spinae plane (ESP) block group
Local anaesthetic infiltration utilising 1% lidocaine will occur, and an 80mm 22G block needle will be inserted using an in-plane cranial to caudad approach, the needle will be advanced to target the interfascial plane deep to the erector spinae muscle at the T2 transverse process. Once the needle tip is in the correct position, 20 ml of the local anaesthetic (ropivacaine 0.5% with 1:400,000 epinephrine) will be administered slowly in 5 ml aliquots under frequent aspiration and correct spread in the interfascial plane will be observed. |
80mm 22G block needle will be inserted using an in-plane cranial to caudad approach, the needle will be advanced to target the interfascial plane deep to the erector spinae muscle at the T2 transverse process. Once the needle tip is in the correct position, 20 ml of the local anaesthetic (ropivacaine 0.5% with 1:400,000 epinephrine) will be administered slowly in 5 ml aliquots under frequent aspiration and correct spread in the interfascial plane will be observed. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Acute postoperative pain at rest
Prazo: 24 hours postoperatively
|
Following breast surgery, measured as an area under the curve (AUC) of rest pain scores VAS scale where 0 corresponds to no pain, and 10 corresponds to worst pain imaginable |
24 hours postoperatively
|
|
Quality of postoperative recovery (QoR 15)
Prazo: 24 hours post-surgery
|
Quality of recovery at 24 hours: questionnaire (0-10, where 0 = none of the time [poor] and 10 = all of the time [excellent]) |
24 hours post-surgery
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Postoperative pain scores
Prazo: 0, 6, 12, 18, 24 and 48 hours post-operatively
|
VAS scale where 0 corresponds to no pain, and 10 corresponds to worst pain imaginable |
0, 6, 12, 18, 24 and 48 hours post-operatively
|
|
Intraoperative opioid consumption
Prazo: During the procedure
|
Cumulative oral morphine equivalent after surgery |
During the procedure
|
|
Postoperative opioid consumption
Prazo: 12,24,48 hours, 7 days postoperative
|
Cumulative oral morphine equivalent after surgery |
12,24,48 hours, 7 days postoperative
|
|
Duration of phase I (PACU) and phase II (surgical day care, SDC) stay
Prazo: From end of surgical procedure to 24 hours after surgery
|
How fast is the recovery is-expressed in minutes |
From end of surgical procedure to 24 hours after surgery
|
|
Opioid-related side effects
Prazo: End of surgical procedure to 48 hours after surgery
|
Risk of opioid-related side effects(nausea, vomiting, pruritis) |
End of surgical procedure to 48 hours after surgery
|
|
Persistent post surgical pain DN4 screening tool
Prazo: 3 months post operatively
|
Satisfaction with pain management. Is prescribed pain medication enough? |
3 months post operatively
|
|
Block-related complications
Prazo: End of surgical procedure to 48 hours after surgery
|
bruising at injection site, numbness over lateral chest, weakness of shoulder or arm, pain/swelling at injection site |
End of surgical procedure to 48 hours after surgery
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Richard Brull, MD,FRCPC, Women's College Hospital
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 2021-0048-B
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .